AU2022379612A1 - Malaria vaccine formulations - Google Patents
Malaria vaccine formulations Download PDFInfo
- Publication number
- AU2022379612A1 AU2022379612A1 AU2022379612A AU2022379612A AU2022379612A1 AU 2022379612 A1 AU2022379612 A1 AU 2022379612A1 AU 2022379612 A AU2022379612 A AU 2022379612A AU 2022379612 A AU2022379612 A AU 2022379612A AU 2022379612 A1 AU2022379612 A1 AU 2022379612A1
- Authority
- AU
- Australia
- Prior art keywords
- months
- dose
- antigen
- immunogenic composition
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163271420P | 2021-10-25 | 2021-10-25 | |
| US63/271,420 | 2021-10-25 | ||
| US202163281332P | 2021-11-19 | 2021-11-19 | |
| US63/281,332 | 2021-11-19 | ||
| PCT/US2022/078665 WO2023076907A1 (en) | 2021-10-25 | 2022-10-25 | Malaria vaccine formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022379612A1 true AU2022379612A1 (en) | 2024-05-09 |
Family
ID=86158498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022379612A Pending AU2022379612A1 (en) | 2021-10-25 | 2022-10-25 | Malaria vaccine formulations |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240415947A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4422676A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024539520A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240099337A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022379612A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023076907A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2346523A4 (en) * | 2008-10-01 | 2014-12-31 | Us Health | MULTIPLE VACCINE VACCINATE AGAINST MALARIA TO CREATE LONG-TERM IMMUNE RESPONSE AGAINST PLASMODIA |
| WO2014111733A1 (en) * | 2013-01-21 | 2014-07-24 | Isis Innovation Limited | Composition and uses thereof |
| WO2019021013A1 (en) * | 2017-07-27 | 2019-01-31 | Oxford University Innovation Limited | ANTIMALARIAL VACCINE |
| AU2019410737A1 (en) * | 2018-12-21 | 2021-06-10 | CureVac SE | RNA for malaria vaccines |
-
2022
- 2022-10-25 US US18/704,632 patent/US20240415947A1/en active Pending
- 2022-10-25 WO PCT/US2022/078665 patent/WO2023076907A1/en not_active Ceased
- 2022-10-25 JP JP2024548682A patent/JP2024539520A/ja active Pending
- 2022-10-25 EP EP22888437.5A patent/EP4422676A4/en active Pending
- 2022-10-25 AU AU2022379612A patent/AU2022379612A1/en active Pending
- 2022-10-25 KR KR1020247017200A patent/KR20240099337A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4422676A1 (en) | 2024-09-04 |
| US20240415947A1 (en) | 2024-12-19 |
| WO2023076907A1 (en) | 2023-05-04 |
| JP2024539520A (ja) | 2024-10-28 |
| KR20240099337A (ko) | 2024-06-28 |
| EP4422676A4 (en) | 2025-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69228698T2 (de) | HYBRIDES PROTEIN ZWISCHEN CS AUS PLASMODIUM UND HBsAG | |
| NZ520976A (en) | Vaccine compositions | |
| US20180028635A1 (en) | Composition and uses thereof | |
| JP7783222B2 (ja) | 呼吸器疾患を治療するための方法および組成物 | |
| US20250230197A1 (en) | Malaria vaccine | |
| JP2021518353A (ja) | 多価インフルエンザナノ粒子ワクチン | |
| US20240415947A1 (en) | Malaria vaccine formulations | |
| KR20250175335A (ko) | Sars-cov-2 백신 조성물 | |
| CN118647395A (zh) | 疟疾疫苗制剂 | |
| US20240408187A1 (en) | Methods and compositions for treating and preventing malaria | |
| US20250325646A1 (en) | Compositions and methods for inducing an immune response against epstein-barr virus | |
| AU2020229815B2 (en) | Methods for preventing disease or disorder caused by RSV infection | |
| OA20058A (en) | Malaria vaccine. | |
| JPWO2015133467A1 (ja) | C型肝炎ウイルスのワクチン及び診断に用いるためのHBc/HCV E2ペプチドキメラタンパク質 |